BG1430U1 - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- BG1430U1 BG1430U1 BG1811U BG181110U BG1430U1 BG 1430 U1 BG1430 U1 BG 1430U1 BG 1811 U BG1811 U BG 1811U BG 181110 U BG181110 U BG 181110U BG 1430 U1 BG1430 U1 BG 1430U1
- Authority
- BG
- Bulgaria
- Prior art keywords
- pharmaceutical formulation
- hifn
- formulation
- pharmacopoeial
- stabilizers
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The utility model relates to a pharmaceutical formulation which suppresses the activity of endogenous human interferon-? (hIFN-?) in diseases associated with abnormal hIFN-? production, in particular, auto-immune diseases and post-transplant atherosclerosis. The formulation presents in a lyophilized state for parenteral administration and includes recombinant protein, pharmacopoeial buffers and stabilizers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG1811U BG1430U1 (en) | 2010-06-25 | 2010-06-25 | Pharmaceutical formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG1811U BG1430U1 (en) | 2010-06-25 | 2010-06-25 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BG1430U1 true BG1430U1 (en) | 2011-04-29 |
Family
ID=45877018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG1811U BG1430U1 (en) | 2010-06-25 | 2010-06-25 | Pharmaceutical formulation |
Country Status (1)
Country | Link |
---|---|
BG (1) | BG1430U1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US82138A (en) * | 1868-09-15 | Improvement in liquid-metees | ||
WO1995030435A2 (en) * | 1994-05-10 | 1995-11-16 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
CA2361081A1 (en) * | 1999-01-20 | 2000-07-27 | The University Of Queensland | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis |
-
2010
- 2010-06-25 BG BG1811U patent/BG1430U1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US82138A (en) * | 1868-09-15 | Improvement in liquid-metees | ||
WO1995030435A2 (en) * | 1994-05-10 | 1995-11-16 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
CA2361081A1 (en) * | 1999-01-20 | 2000-07-27 | The University Of Queensland | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010226A (en) | Lipid nanoparticle compositions and methods for mrna delivery. | |
EP4276180A3 (en) | Clostridium histolyticum enzyme | |
NZ600709A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
PH12016500011A1 (en) | Cells for producing recombinant iduronate-2-sulfatase | |
PH12015501421B1 (en) | Long-acting formulations of insulins | |
WO2012047733A3 (en) | Treatment of acne by conditioned media | |
BR112013023756A2 (en) | mutant cells for protein secretion and lignocellulose degradation | |
NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
WO2012000103A8 (en) | Methods of targeting pten mutant diseases and compositions therefor | |
NZ610556A (en) | Stem cell suspension | |
NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
MX2013002725A (en) | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle. | |
NZ597580A (en) | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof | |
AU2016219650A1 (en) | Compositions and methods for extended therapy with aminopyridines | |
EP2558124A4 (en) | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization | |
BR112014015933A2 (en) | methods and materials to reduce recombinant protein degradation | |
WO2012115903A3 (en) | Yeast strain for the production of proteins with modified o-glycosylation | |
BR112014010053A2 (en) | Isoprene synthase variants with enhanced solubility for isoprene production | |
BR112014021326A2 (en) | cell for protein expression, method for reducing peptide amidation activity in a given cell, use of a cell | |
WO2014072720A3 (en) | Cell differentiation | |
BG1430U1 (en) | Pharmaceutical formulation | |
IN2014MN02461A (en) | ||
MX2012012489A (en) | Preparation of polypeptides and salts thereof. | |
EP3065705A4 (en) | Compositions and methods for administration of an enzyme to a subject's airway | |
WO2012129449A3 (en) | High level production of recombinant proteins |